• SENSEX 72,529.07
    -242.65 (--0.33%)
  • BANKNIFTY 54,259.95
    -211.70 (--0.39%)
  • Cube Highways
    156.41 162.00(%)
  • NSE
    1,793.70 1,878.00(%)
  • 360 ONE
    1,019.75 906.20(%)
  • SS Retail
    775.00 888.00(%)
  • Cupid
    292.35 298.95(%)
  • R Systems Intl.
    305.25 446.55(%)
  • GE Vernova T&D
    4,225.00 5,650.00(%)
  • Lords Mark Industries
    84.89 60.00(%)
  • PB Fintech.
    1,076.35 1,076.35(%)
  • Azad Engineering
    2,997.65 2,997.65(%)
  • Hero Motors
    140.75 156.03(%)
  • HDFC Bank
    720.00 1,020.35(%)
  • Reliance Industries
    1,182.05 1,182.05(%)
  • Delhivery
    418.15 524.25(%)
  • Ather Energy
    1,404.00 542.20(%)
  • Varmora Granito
    163.45 163.45(%)
  • Bharti Airtel
    1,788.00 2,174.70(%)
  • Indian Hotels Co
    725.50 757.10(%)
  • ICICI Lombard
    1,498.00 1,423.95(%)
  • Bajaj Finance
    961.65 788.40(%)
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison
Overview
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison

Rubicon Research Ltd Pharmaceuticals - Indian - Formulations

  • Indian Private
  • BSE Code : 34163.0
  • ISIN : INE506V01022
1,609.00 16 (1.02%)
  • As on 29 Sep 2026 (EOD)

  • Today’s Low

    1,583.20

  • Today’s High

    1,646.40

  • Open

    1,593.60

  • Perv Close

    1,592.80

  • 52W Low

    570.75

  • 52W High

    1,899.00

Key Indicators

  • P/E(TTM)

    113.51

  • Mar.Cap (₹Cr.)

    26,634.08

  • Div & Yield %

    0.09

  • Book Value(₹)

    81.76

  • Debt-Equity Ratio

    1.02

  • AGM Date

    29-Sep-2026

  • EPS

    14.22

  • P/E Ratio

    113.51

Financials Ratios

  • Debt-Equity Ratio

    1.11

  • Mar.Cap (₹Cr.)

    26,634.08

  • RONW (%)

    27.11

  • ROCE (%)

    18.42

Score Board

  • Equity (₹ in Cr.)

    16.55

  • BV (₹)

    81.80

  • Sales( ₹ in Cr.)

    1,306.08

  • NP (in Cr.)

    188.89

  • NP Var(%)

    12.0

  • Div%

    150.0

  • CPS (₹)

    13.70

  • EPS (₹)

    11.40

  • Traded Value (₹ in Lakhs)

    26,718.51

  • 52 Week High

    1,899.00

  • 52 Week Low

    570.75

  • Price BSE

    1614.0

  • Price NSE

    1,609.00

  • Market Capital( in Cr.)

    26,718.51

  • P/C Ratio

    117.90

  • P/E Ratio

    141.40

  • Price Vs.BV

    11.40

View More
Invest Now!

Navigate The Market With Confidence

Your all-in-one destination for expert investment guidance and streamlined portfolio management solutions

Financials

All Values are in (₹Cr)
Particulars(INCOME) 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar
INCOME :            
Sales Turnover 1,306.08 1,073.84 630.51 393.52 400.04 331.35
Excise Duty 0.00 0.00 0.00 0.00 0.00 0.00
Net Sales 1,306.08 1,073.84 630.51 393.52 400.04 331.35
Other Income 10.83 19.68 26.43 25.48 17.38 10.74
Stock Adjustments 33.36 10.94 10.70 49.24 -8.75 5.83
Total Income 1,350.27 1,104.46 667.64 468.24 408.67 347.92
EXPENDITURE :            
Raw Materials 381.08 319.22 225.15 149.40 94.55 61.15
Power and Fuel Cost 24.25 20.01 18.31 15.71 10.19 6.54
Employee Cost 164.27 127.74 84.71 97.12 59.29 41.29
Other Manufacturing Expenses 132.88 89.09 60.55 50.11 40.30 21.46
Selling and Administration Expenses 307.11 250.73 171.79 104.28 83.51 63.76
Miscellaneous Expenses 19.20 8.10 7.58 7.66 63.39 31.58
Employee Benefit Expenses 164.27 127.74 84.71 97.12 59.29 41.29
Less: Preoperative Expenditure 0.00 0.00 0.00 0.00 0.00 0.00
Total Expenses 1,028.78 814.89 568.09 424.28 351.21 225.77
Operating Profit 321.49 289.58 99.56 43.97 57.45 122.15
Interest 30.96 34.29 30.53 18.96 9.02 9.00
Gross Profit 290.53 255.29 69.03 25.01 48.43 113.15
Depreciation 37.75 32.01 34.95 36.06 31.51 27.77
Profit Before Tax 252.78 223.28 34.08 -11.05 16.92 85.38
Current Tax 68.43 57.92 11.24 8.32 2.78 21.18
Fringe Benefit tax 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax -3.81 -2.18 -1.51 -2.48 -2.54 11.25
Reported Net Profit 188.17 167.54 24.35 -16.89 16.68 52.96
Extraordinary Items -0.73 -0.85 0.01 0.03 0.36 0.00
Adjusted Net Profit 188.90 168.39 24.34 -16.92 16.32 52.96
Adjustment below Net Profit 6.23 1.96 0.00 0.00 0.01 -0.04
P & L Balance brought forward 368.28 199.09 174.99 42.49 146.18 94.26
Statutory Appropriations 0.00 0.00 0.00 0.00 0.00 0.00
Appropriations 0.31 0.30 0.25 0.25 0.51 1.00
P & L Balance carried down 562.36 368.28 199.09 25.34 162.36 146.18
Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Preference Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Equity Dividend (%) 150.00 2.00 2.00 5.00 0.00 0.00
Dividend Per Share(Rs) 1.50 0.02 0.02 0.50 0.00 0.00
Earnings Per Share-Unit Curr 11.40 10.87 1.60 -33.31 32.91 104.46
Earnings Per Share(Adj)-Unit Curr 11.40 - - - - -
Book Value 81.97 43.33 31.29 564.84 845.39 811.56
Book Value(Adj)-Unit Curr 81.97 - - - - -

Shareholding Pattern

  • Promoter Group

    59.76%

  • Public Share Holding

    40.24%

Category of Shareholder No of Shares % Holdings Demat Shares Shareholders
A]. Promoter & Group
Foreign (Promoter & Group) - Bodies Corporate 59,258,360 35.83 59,258,360 1
Foreign (Promoter & Group)-Individuals (Non-Resident / Foreign) 0 0.00 0 0
Foreign Promoter(Institutional) 0 0.00 0 0
Promoter Others 0 0.00 0 0
Sub Total 59,258,360 35.83 59,258,360 1
[2] INDIAN
Bodies Corporate-Indian (Promoter & Group) 0 0.00 0 0
Government(Central / State)-Indian (Promoter & Group) 0 0.00 0 0
Directors & their Relatives-Indian (Promoter & Group) 0 0.00 0 0
Financial Institutions / Banks-Indian (Promoter & Group) 0 0.00 0 0
Individuals / Hindu Undivided Family-Indian (Promoter & Group) 39,060,000 23.62 39,060,000 5
Partnership Firms-Indian (Promoter & Group) 510,000 0.31 510,000 1
Persons Acting in Concert 0 0.00 0 0
Trusts 0 0.00 0 0
Others 0 0.00 0 0
Sub Total 39,570,000 23.93 39,570,000 6
Total ShareHolding for Promoter & Group
B]. Publice Share Holding
1] Institution
Government(Central / State) 0 0.00 0 0
Clearing Members 0 0.00 0 0
Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
Financial Institutions / Banks 0 0.00 0 0
Foreign Bank 0 0.00 0 0
Foreign Bodies Corporate/OCBs/FBC 0 0.00 0 0
Foreign Collaborators 0 0.00 0 0
Foreign Institutional Investors 12,432,126 7.52 12,432,126 39
Foreign Venture Capital Investors 0 0.00 0 0
Foreign Institution Other 0 0.00 0 0
Insurance Companies 305,620 0.18 305,620 1
Mutual Funds / UTI 11,953,335 7.23 11,953,335 14
Individuals (Non-Resident / Foreign) 0 0.00 0 0
NSDL Intransit 0 0.00 0 0
Others 3,334,215 2.02 3,334,215 14
Trusts 0 0.00 0 0
Venture Capital Funds 0 0.00 0 0
Sub total 28,025,296 16.95 28,025,296 68
2] Non Institution
Bodies Corporate 285,201 0.17 285,201 166
Clearing Members 37,841 0.02 37,841 13
Directors of their Relatives 0 0.00 0 0
Employees 0 0.00 0 0
Escrow Account 0 0.00 0 0
Foreign Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
NRIs/Foreign Individuals/Foreign Nationals 2,926,041 1.77 2,926,041 670
Foreign Non Institution Other 6,605,156 3.99 6,605,156 2
Hindu Undivided Families 22,512,251 13.61 22,512,251 961
Indian Public 0 0.00 0 0
Individuals holding nominal share capital in excess of Rs. 1 lakh 499,816 0.30 499,816 2
Individuals holding nominal share capital up to Rs. 1 lakh 5,219,645 3.16 5,219,645 41,326
Market Maker 0 0.00 0 0
NSDL Transit 0 0.00 0 0
Shares in transit 0 0.00 0 0
Societies 0 0.00 0 0
Trust & Foundation 0 0.00 0 0
Others 335,901 0.20 335,901 1
Sub Total 38,529,094 23.30 38,529,094 43,179
Total Public Shareholding
C]. Shares held by Custodians and against which Depository Receipts have been issued
ADR 0 0.00 0 0
GDR 0 0.00 0 0
Other Custodians 0 0.00 0 0
Total Shares held by Custodians and against which Depository Receipts have been issued 0 0.00 0 0
Grand Total ( A + B + C ) 165,382,750 100.00 165,382,750 43,254

Company Background

Rubicon Research LtdPharmaceuticals - Indian - Formulations

  • Rubicon Research Ltd
  • BSE Code : 34163.0
  • ISIN : INE506V01022

  • Incorporation Year

    1999

  • Registered Office

    Medone House B-75 Road No.33
    Wagle Estate, Thane (West),
    Maharashtra-400604

  • Telephone

    022 6141 4000

  • FAX

  • Chairman

    Venkat Changavalli

  • Managing Director

  • Company Secretary

    Deepashree Tanksale

  • Auditor

    Deloitte Haskins & Sells LLP

  • Face Value

    1

  • Listing

    NSE

  • Registrar

    MUFG Intime India Pvt Ltd
    C-101 247 Park,
    L B S Marg,Vikhroli West
    Mumbai - Mumbai-400083

Rubicon Research Ltd Peer Comparison

Profit & Loss
Financial Ratios
Balance Sheet
Select Company Name LTP (₹) Revenue Sales P/E Ratio ROCE %
Rubicon Research 1,614.10 1,316.91 1,306.08 113.51 20.82
Abbott India 27,266.65 7,217.19 6,929.05 35.88 43.78
Astrazeneca Phar 6,254.35 2,304.07 2,275.58 92.18 27.86
Glaxosmi. Pharma 2,787.25 3,932.76 3,790.20 44.52 58.17
Novartis India 1,933.35 393.10 354.33 48.82 15.94
Cipla 1,383.00 20,102.60 18,979.95 36.35 13.88
Bliss GVS Pharma 710.05 773.53 729.81 65.99 12.51
Fermenta Biotec. 549.30 474.15 450.25 25.64 18.77
Amrutanjan Healt 506.15 520.13 502.55 27.11 24.16
Guj. Themis Bio. 404.40 168.25 165.82 108.13 18.05
Ambalal Sarabhai 39.24 19.52 3.94 72.67 6.77